Creo Medical Group PLC (LON:CREO - Get Free Report) insider Kevin Crofton bought 701,750 shares of Creo Medical Group stock in a transaction dated Friday, May 30th. The stock was purchased at an average price of GBX 16 ($0.22) per share, with a total value of £112,280 ($152,161.54).
Creo Medical Group Price Performance
LON CREO traded down GBX 0.19 ($0.00) during trading hours on Thursday, reaching GBX 15.81 ($0.21). The company's stock had a trading volume of 317,985 shares, compared to its average volume of 1,369,490. The company has a debt-to-equity ratio of 29.96, a quick ratio of 2.19 and a current ratio of 3.24. The company's 50-day moving average is GBX 11.27 and its two-hundred day moving average is GBX 14.79. Creo Medical Group PLC has a fifty-two week low of GBX 9.22 ($0.12) and a fifty-two week high of GBX 37.20 ($0.50). The stock has a market cap of £63.91 million, a PE ratio of -2.50 and a beta of 0.86.
Creo Medical Group (LON:CREO - Get Free Report) last released its quarterly earnings results on Monday, May 19th. The company reported GBX (8) (($0.11)) EPS for the quarter. Creo Medical Group had a negative net margin of 73.93% and a negative return on equity of 41.79%. Analysts forecast that Creo Medical Group PLC will post -10.0800005 EPS for the current year.
Creo Medical Group Company Profile
(
Get Free Report)
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.
See Also
Before you consider Creo Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.
While Creo Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
